New Jersey A3242 mandates health benefits coverage for continuous glucose monitoring systems for glycogen storage disease treatment.
New Jersey A3242 requires health insurers to cover expenses for continuous glucose monitoring systems for treating glycogen storage disease. This applies to various health benefit plans, including those from health, hospital, and medical service corporations, commercial individual and group health insurers, health maintenance organizations, and specific state health benefits programs. The coverage must be provided to the same extent as for any other medical condition. The act takes effect seven months after its enactment.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.